Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

Astra, led by boss Pascal Soriot (pictured), said it is accelerating its expansion in US with an investment that will create ...

Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans and examine the risk factors for intensive care unit (ICU) admission and ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Vermont has the second lowest state fatality rate in the US (148.4 per 100K; Hawaii 113.7/100K). Mississippi (466/100K) and ...

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...

Vicebio, a biopharmaceutical company that develops vaccines for serious respiratory viral infections, has agreed to be ...

French pharma major Sanofi today announced it has entered into an agreement to acquire Vicebio, a privately held biotechnology company headquartered in London, UK.